argenx SE American Depositary Shares closed at $981.33 on Nov 12, up 0.38%, 7.3% below its 52-week closing high. Volume of 449.4K shares was 1.06× its 20-day average (close to normal).
Split-adjusted performance: +19.9% over one month, +19.4% over six months, +10.3% over one year.
Short interest was 1.4M shares at the Oct 30 settlement, up 4.3% from the prior report (3.4 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
